Christina Paiato

Christina Paiato

Auto-generated profile, based on publicly available information

Christina Paiato

Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ETErwin Tomasich
Erwin Tomasich
ASAriane Steindl
Ariane Steindl
CPChristina Paiato
Christina Paiato
THTeresa Hatziioannou
Teresa Hatziioannou
MKMarkus Kleinberger
Markus Kleinberger
ABAnna S. Berghoff
Anna S. Berghoff
Purpose: HER3 belongs to a family of receptor tyrosine kinases with oncogenic properties and is targeted by a variety of novel anticancer agents. There is a huge unmet medical need for systemic treatment options in patients with brain metastases (BM). Therefore, we aimed to investigate HER3 expression in BM of breast (BCa) and non–small cell lung cancer (NSCLC) as the basis for future clinical trial design. Experimental Design: We analyzed 180 BM samples of breast cancer or NSCLC and 47 corresponding NSCLC extracranial tissue. IHC was performed to evaluate protein expression of HER3, and immune cells based on CD3, CD8, and CD68. To identify dysregulated pathways based on differential DNA methylation patterns, we used Infinium MethylationEPIC microarrays. Results: A total of 99/132 (75.0%) of BCa-BM and 35/48 (72.9%) of NSCLC-BM presented with HER3 expression. Among breast cancer, HER2-positive and HER2-low BM showed significantly higher rates of HER3 coexpression than HER2-negative BM (87.1%/85.7% vs. 61.0%, P = 0.004). Among NSCLC, HER3 was more abundantly expressed in BM than in matched extracranial samples (72.9% vs. 41.3%, P = 0.003). No correlation of HER3 expression and intratumoral immune cell density was observed. HER3 expression did not correlate with overall survival from BM diagnosis. Methylation signatures differed according to HER3 status in BCa-BM samples. Pathway analysis revealed subtype-specific differences, such as TrkB and Wnt signaling pathways dysregulated in HER2-positive and triple-negative breast cancer BM, respectively. Conclusions: HER3 is highly abundant in BM of breast cancer and NSCLC. Given the promising results of antibody–drug conjugates in extracranial disease, BM-specific trials that target HER3 are warranted. See related commentary by Kabraji and Lin, p. 2961

25 November 2025
Verified
Other
Open access
ETErwin Tomasich
Erwin Tomasich
ASAriane Steindl
Ariane Steindl
CPChristina Paiato
Christina Paiato
THTeresa Hatziioannou
Teresa Hatziioannou
MKMarkus Kleinberger
Markus Kleinberger
ABAnna S. Berghoff
Anna S. Berghoff
Differentially methylated CpG sites in HER3+ vs HER3- breast cancer samples (HER2+ cohort)

15 August 2023
Verified
Other
Open access
ETErwin Tomasich
Erwin Tomasich
ASAriane Steindl
Ariane Steindl
CPChristina Paiato
Christina Paiato
THTeresa Hatziioannou
Teresa Hatziioannou
MKMarkus Kleinberger
Markus Kleinberger
ABAnna S. Berghoff
Anna S. Berghoff
Differentially methylated CpG sites in HER3+ vs HER3- breast cancer samples (TNBC cohort)

26 April 2023
Verified
Other
Open access
ETErwin Tomasich
Erwin Tomasich
ASAriane Steindl
Ariane Steindl
CPChristina Paiato
Christina Paiato
THTeresa Hatziioannou
Teresa Hatziioannou
MKMarkus Kleinberger
Markus Kleinberger
ABAnna S. Berghoff
Anna S. Berghoff
Purpose:HER3 belongs to a family of receptor tyrosine kinases with oncogenic properties and is targeted by a variety of novel anticancer agents. There is a huge unmet medical need for systemic treatment options in patients with brain metastases (BM). Therefore, we aimed to investigate HER3 expression in BM of breast (BCa) and non–small cell lung cancer (NSCLC) as the basis for future clinical trial design.Experimental Design:We analyzed 180 BM samples of breast cancer or NSCLC and 47 corresponding NSCLC extracranial tissue. IHC was performed to evaluate protein expression of HER3, and immune cells based on CD3, CD8, and CD68. To identify dysregulated pathways based on differential DNA methylation patterns, we used Infinium MethylationEPIC microarrays.Results:A total of 99/132 (75.0%) of BCa-BM and 35/48 (72.9%) of NSCLC-BM presented with HER3 expression. Among breast cancer, HER2-positive and HER2-low BM showed significantly higher rates of HER3 coexpression than HER2-negative BM (87.1%/85.7% vs. 61.0%, P = 0.004). Among NSCLC, HER3 was more abundantly expressed in BM than in matched extracranial samples (72.9% vs. 41.3%, P = 0.003). No correlation of HER3 expression and intratumoral immune cell density was observed. HER3 expression did not correlate with overall survival from BM diagnosis. Methylation signatures differed according to HER3 status in BCa-BM samples. Pathway analysis revealed subtype-specific differences, such as TrkB and Wnt signaling pathways dysregulated in HER2-positive and triple-negative breast cancer BM, respectively.Conclusions:HER3 is highly abundant in BM of breast cancer and NSCLC. Given the promising results of antibody–drug conjugates in extracranial disease, BM-specific trials that target HER3 are warranted.

26 April 2023
Verified
Other
Open access
ETErwin Tomasich
Erwin Tomasich
ASAriane Steindl
Ariane Steindl
CPChristina Paiato
Christina Paiato
THTeresa Hatziioannou
Teresa Hatziioannou
MKMarkus Kleinberger
Markus Kleinberger
ABAnna S. Berghoff
Anna S. Berghoff
Differentially methylated CpG sites in HER3+ vs HER3- breast cancer samples (TNBC cohort)

15 August 2023
Verified
Other
Open access
ETErwin Tomasich
Erwin Tomasich
ASAriane Steindl
Ariane Steindl
CPChristina Paiato
Christina Paiato
THTeresa Hatziioannou
Teresa Hatziioannou
MKMarkus Kleinberger
Markus Kleinberger
ABAnna S. Berghoff
Anna S. Berghoff
Kaplan-Meier curves of patients with BM of A) Luminal-BCa B) HER2+ BCa C) TN-BCa, and D) NSCLC patients stratified according to the intensity of HER3 expression determined by IHC.